tirzepatide mounjaro for type 2 diabetes Can you take with diabetes? New Blockbuster Type 2 Medication

Discussion This observational cohort study describes real-world utilization patterns and characteristics of patients dispensed an SGLT2i or GLP-1 RA in the US using data from Optum CDM in the period following changes to the landscape for treatment and prevention of CKD in type 2 diabetes (later period, July 2021September 2023) as well as temporal changes in utilization and baseline characteristics relative to the period prior (earlier period, January 2012June 2021)

Bypassing the Weight Loss Narrative : Through secondary analyses, Northwestern scientists proved a vital mechanistic point: weight loss alone does not explain the increased risk of low blood pressure

Self-administration preference

Referenced Citations Teichman, S